Mark Lawler, PhD, lead study author and professor at Belfast, Ireland-based Queen’s University, and colleagues showed how defining gene signatures within bowel cancer cells allows for the development of prognostic and predictive bowel cancer markers.
Here’s what you should know.
1. Researchers analyzed molecular and genetic data from patients’ tissues and “discovered that there are different subtypes of bowel cancer,” Dr. Philip Dunne, Queen’s University senior research fellow, said in a release.
When researchers identify the cancer cells biological makeup, they can tailor treatments to each specific patient, maximizing effectiveness while limiting side effects.
2. Researchers performed the research as part of the MRC-Cancer Research UK stratified medicine consortium. Several researchers throughout the U.K. were part of the research.
3. The researchers are going to further develop their research with hopes of making it a standard practice.
More articles on gastroenterology:
Craig Campbell to hold ‘Cornhole Challenge’ for Fight Colorectal Cancer — 3 insights
GI leader to know: Dr. Adrienne Scheich of Ann & Robert H. Lurie Children’s Hospital
American Cancer Society Nutrition and Physical Activity guidelines increases colon cancer survival rates — 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
